Reuters logo
BRIEF-Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement
October 18, 2017 / 12:59 PM / a month ago

BRIEF-Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement

Oct 18 (Reuters) - Arbutus Biopharma Corp:

* Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement to develop novel RNA-based personalized neoantigen immunotherapies for cancer patients

* Arbutus Biopharma Corp - is deploying proprietary lipid nanoparticle technology to deliver gritstone’s rna-based neoantigen immunotherapy products​

* Arbutus Biopharma - ‍under terms of license agreement, gritstone obtains worldwide access to arbutus’ portfolio of proprietary and LNP products​

* Arbutus Biopharma - ‍Gritstone will pay co upfront payment, payments for achievement of development, regulatory, and commercial milestones Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below